Do Options Traders Know Something About Alarm.com Stock We Don't?
Source: zacks.com

Alarm.com's Dec. 18, 2026 $35 call is among the equity options with the highest implied volatility, signaling that traders are pricing in a potentially large move in the shares. Fundamentally, the company holds a Zacks Rank #1 (Strong Buy), while two analysts raised current-quarter EPS estimates over the past 60 days and none cut them, lifting consensus EPS to $0.90 from $0.77. The elevated volatility may create premium-selling opportunities, but it does not indicate the direction of the anticipated move.
Analysis
The unusually high implied volatility in a single, long-dated $35 ALRM call is not a reliable directional signal without open interest, bid/ask width, trade size, and comparison against adjacent strikes. A deep-in-the-money or thinly traded LEAPS contract can show mechanically distorted IV; treating it as informed positioning would be a category error. The estimate increase is supportive for the next earnings print, but two upward revisions do not establish a durable earnings-revision cycle or justify multiple expansion on their own.
Near term, the relevant mechanism is whether higher estimates reflect recurring SaaS/monitoring attach rates and ARPU rather than hardware pull-forwards or one-off partner demand. If recurring revenue and adjusted EBITDA guidance rise together, ALRM can outperform security-system peers such as ADT and Resideo (REZI), whose economics carry more customer-acquisition, installation, or hardware-cycle exposure. Conversely, elevated long-dated vol may be pricing an unobservable corporate, customer-concentration, or competitive risk; a miss in subscription growth would pressure both earnings expectations and the premium software valuation simultaneously.
Consensus appears too willing to infer an event from IV alone. The more actionable signal is the relationship between ALRM's implied move into earnings, realized post-earnings moves, and the revision breadth over the next 30-60 days. Without confirmation that option volume is opening activity and that revisions broaden beyond two analysts, this is a monitoring setup rather than a standalone alpha opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
Key Decisions for Investors
- Do not initiate a directional ALRM position solely from the cited LEAPS IV; first verify open-interest change, executable bid/ask spreads, and IV versus neighboring December 2026 strikes. Treat a one-strike anomaly as stale or illiquid until proven otherwise.
- Establish a 30-60 day ALRM earnings-revision watch: consider a tactical long only if consensus EPS/revenue estimates continue to rise and management raises recurring-revenue or EBITDA guidance. Falsify on flat-to-down subscription growth or guidance maintained despite the higher consensus.
- If ALRM's next earnings implied move is materially above its prior four-quarter realized move and the option chain is liquid, evaluate a defined-risk short-vol structure such as an iron condor after confirming no scheduled corporate catalyst. Size small; exit if the stock breaches the short strike or revision momentum accelerates.
- For a fundamentals-confirmed relative-value expression, prefer long ALRM / short REZI only after ALRM demonstrates recurring-revenue acceleration versus hardware-led growth. Reassess if REZI's organic growth or margin guidance improves faster than ALRM's subscription metrics.
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Bank of America says Brent crude oil could top $150 a barrel if Iran war disruptions persist
- Morgan Stanley thinks investors should diversify into these markets
- Sullivan: Wall Street admits it doesn't know where oil is headed. There's one stock they do agree on
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Heidi CEO on AI in Healthcare, $900M valuation